Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + bevacizumab for unresectable mucosal melanoma (China, phase II)
CTR20191516Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in mucosal melanoma (MM), sponsored by Roche. Started Aug 2019; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on CTR20191516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191516.